Last updated: February 25, 2026
What Is the Market Status of Dalfopristin-Quinupristin?
Dalfopristin-quinupristin (brand name Synercid) is a combination antibiotic used primarily against infections caused by resistant gram-positive bacteria, including vancomycin-resistant Enterococcus faecium. It was approved by the FDA in 1999. Currently, its global sales face decline due to emerging resistance, limited indications, and replacement by newer agents.
Regulatory and Patent Landscape
| Aspect |
Details |
| FDA Approval |
1999 |
| Patent Expiry |
Around 2010-2012; no extended exclusivity from biosimilars |
| Regulatory Status |
Approved in multiple countries; market access varies by region |
| Orphan Status |
Not designated as orphan drug |
Patent expiries have exposed the drug to generic competition, reducing revenues. Newly granted patents or exclusivities are lacking, limiting patent-driven investment incentives.
Clinical and Market Needs
The drug’s primary use is in treating complicated skin and soft tissue infections, bacteraemia, and endocarditis caused by resistant bacteria. Market penetration remains limited by:
- Resistance development diminishing effectiveness
- Toxicity concerns limiting use
- Competition from newer antibiotics like linezolid or daptomycin
Competitive Landscape
| Competitors |
Market Share (estimated) |
Key Attributes |
| Linezolid (Zyvox) |
30-40% |
Oral formulation, broader indications, newer approval |
| Daptomycin (Cubicin) |
20-25% |
Potent bactericidal, less toxicity |
| Tigecycline (Tygacil) |
10-15% |
Broad-spectrum, oral availability in some regions |
| Dalfopristin-Quinupristin |
1-5% |
Limited due to resistance and toxicity issues |
Market share for dalfopristin-quinupristin remains minimal, highlighting its niche role and limited growth potential.
Financial and R&D Investment Considerations
The therapy's revenue potential is declining. Historically, peak sales figures in the US hovered around $100-$150 million annually, now decreasing to under $50 million. Depressed sales, combined with high manufacturing costs, make future R&D investments unattractive.
Recent R&D efforts into derivatives or new formulations have not yielded promising results, and no new clinical trials are ongoing. The low barrier to generic entry diminishes return expectations for potential lifecycle extensions.
Investment Risks
- Market Saturation: Off-patent status with multiple generics reduces profitability.
- Resistance Development: Evolution of resistant strains diminishes clinical utility.
- Adoption Barriers: Toxicity and complex administration limit broader use.
- Competitive Pressure: Emerging antibiotics with better profiles overshadow existing therapies.
Strategic Implications
Investors should consider that investment in dalfopristin-quinupristin is largely unviable without repositioning or reformulation initiatives. A focus on companies researching resistance mitigation or novel drug delivery systems may present better opportunities. The overall declining market and high competition favor asset divestment over long-term investment.
Key Takeaways
- Dalfopristin-quinupristin was FDA-approved in 1999 for resistant gram-positive infections.
- Patent expiries and the advent of newer agents have significantly reduced its market share.
- The drug faces resistance issues, toxicity concerns, and competition, constraining growth.
- Financial prospects are limited as sales decline, and no active R&D or patent extensions are ongoing.
- Investment risk remains high due to market saturation, resistance, and competitive threats.
Frequently Asked Questions
1. Is there potential for dalfopristin-quinupristin to regain market share?
Current data suggest limited potential due to resistance, safety profile, and competition from newer antibiotics.
2. Are there ongoing clinical trials or developments for this drug?
No recent or ongoing clinical trials are publicly reported indicating pipeline activity.
3. Can biosimilars or generics extend the drug’s profitability?
Generic versions dominate the market, reducing pricing power and profitability.
4. What are the main competitors surpassing dalfopristin-quinupristin?
Linezolid and daptomycin are leading due to broader indications, safety, and ease of administration.
5. How does resistance impact future investment decisions?
Resistance reduces clinical utility, diminishes sales, and discourages further R&D investments.
Citations
- U.S. Food and Drug Administration. (1999). FDA approval for Synercid.
- MarketLine. (2022). Global Antibiotics Market Analysis.
- IQVIA. (2022). Pharmaceutical Market Reports.
- EMA. (2010). Summary of Product Characteristics for Dalfopristin-Quinupristin.
- Statista. (2022). Antibiotics Market Share in the US.
[1] U.S. Food and Drug Administration. (1999). FDA Approvals.
